Kymera Therapeutics, Inc. (KYMR)

Market Cap	2.63B
Revenue (ttm)	87.56M
Net Income (ttm)	-167.47M
Shares Out	64.77M
EPS (ttm)	-2.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	957,918
Open	38.66
Previous Close	39.14
Day's Range	38.24 - 40.78
52-Week Range	22.35 - 53.27
Beta	2.17
Analysts	Buy
Price Target	54.00 (+32.81%)
Earnings Date	Feb 20, 2025

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 187
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR
• Website: https://www.kymeratx.com

Financial Performance

In 2023, Kymera Therapeutics's revenue was $78.59 million, an increase of 67.84% compared to the previous year's $46.83 million. Losses were -$146.96 million, -5.07% less than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $54.0, which is an increase of 32.81% from the latest price.

Price Target

$54.0

(32.81% upside)

Analyst Consensus: Buy